Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention

Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and additional risk factors in the pivotal REDUCE-IT trial. Sinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Peter P., Ferrières, Jean, Waters, Max, Mortensen, Martin Bødtker, Lan, Nick S. R., Wong, Nathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/
https://www.ncbi.nlm.nih.gov/pubmed/37719970
http://dx.doi.org/10.3389/fcvm.2023.1220017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501481/
https://www.ncbi.nlm.nih.gov/pubmed/37719970
http://dx.doi.org/10.3389/fcvm.2023.1220017

Ejemplares similares